The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy

References

• Diabetes Branch of Chinese Medical Association. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition). Chin J Diabetes. 2018;10(1):1–8.
   Google Scholar
• Siddiqui MK, Kennedy G, Carr F, et al. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia. 2018;61(6):1344–1353. doi: 10.1007/s00125-018-4601-7.
   PubMed Web of Science ®Google Scholar
• Moschos MM, Pantazis P, Gatzioufas Z, et al. Association between platelet activating factor acetylhydrolase and diabetic retinopathy: does inflammation affect the retinal status? Prostaglandins Other Lipid Mediat. 2016;122:69–72. doi: 10.1016/j.prostaglandins.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Fortunato J, Bláha V, Bis J, et al. Lipoprotein-associated phospholipase A(2) mass level is increased in elderly subjects with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:278063. doi: 10.1155/2014/278063.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Momeni A, Shahidi S, Seirafian S, et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4(2):128–132.
   PubMed Web of Science ®Google Scholar
• Bartels H, Böhmer M, Heierli C. Serum creatinine determination without protein precipitation. Clin Chim Acta. 1972;37:193–197. doi: 10.1016/0009-8981(72)90432-9.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi: 10.2215/CJN.11491116.
   PubMed Web of Science ®Google Scholar
• Tuttle KR. Back to the future: glomerular hyperfiltration and the diabetic kidney. Diabetes. 2017;66(1):14–16. doi: 10.2337/dbi16-0056.
   PubMed Web of Science ®Google Scholar
• Elsherbiny NM, Galil KHAE, Gabr MM, et al. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur Cytokine Netw. 2012;23(3):78–86. doi: 10.1684/ecn.2012.0309.
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Kleefstra N, Groenier KH, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLOS One. 2012;7(7):e40427. doi: 10.1371/journal.pone.0040427.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. doi: 10.1038/nature05482.
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605. doi: 10.1161/CIRCULATIONAHA.106.621854.
   PubMed Web of Science ®Google Scholar
• Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–340. doi: 10.1038/nrneph.2011.51.
   PubMed Web of Science ®Google Scholar
• Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, et al. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015;2015:948417. doi: 10.1155/2015/948417.
   PubMed Web of Science ®Google Scholar
• MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the ­oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338(2):479–487. doi: 10.1042/bj3380479.
   PubMedGoogle Scholar
• Li D, Zhao L, Yu J, et al. Lipoprotein-associated phospholipase A2 in coronary heart disease: review and meta-analysis. Clin Chim Acta. 2017;465:22–29. doi: 10.1016/j.cca.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Leung WK, Gao L, Siu PM, et al. Diabetic nephropathy and endothelial dysfunction: current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study. Life Sci. 2016;166:121–130. doi: 10.1016/j.lfs.2016.10.015.
   PubMed Web of Science ®Google Scholar
• Acharya NK, Qi X, Goldwaser EL, et al. Retinal pathology is associated with increased blood–retina barrier permeability in a diabetic and hypercholesterolaemic pig model: beneficial effects of the Lp-PLA2 inhibitor darapladib. Diab Vasc Dis Res. 2017;14(3):200–213. doi: 10.1177/1479164116683149.
   PubMed Web of Science ®Google Scholar
• Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):117–124. doi: 10.2174/1570161117666190502103733.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li TT, Zhou W, et al. Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease. Diabetes Res Clin Pract. 2019;150:194–201. doi: 10.1016/j.diabres.2019.03.026.
   PubMed Web of Science ®Google Scholar
• Xu RX, Zhang Y, Li XL, et al. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Clin Chim Acta. 2015;446:195–200. doi: 10.1016/j.cca.2015.04.032.
   PubMed Web of Science ®Google Scholar
• Wang YZ, Ren LJ, Ni WJ. Correlation of the combined detection of Lp-PLA2, hs-CRP and early kidney disease in type 2 diabetes. Chin J Pract Med. 2017;44(2):27–29.
   Google Scholar
• Zhang WY, Lu Y, Zhang QQ, et al. The value of lipoprotein-associated phospholipase A2 and cystatin C in early diagnosis of diabetic kidney disease. Chin J Diabetes. 2021;29(8):601–605.
   Google Scholar
• Garg S, Madhu SV, Suneja S. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type-2 diabetes mellitus. Indian J Med Res. 2015;141(1):107–114. doi: 10.4103/0971-5916.154512.
   PubMedGoogle Scholar
• Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006;20(6):343–348. doi: 10.1016/j.jdiacomp.2006.07.004.
   PubMed Web of Science ®Google Scholar
• Liang G, Wu R, Jiang L, et al. The role of lipoprotein-associated phospholipase A2 in acute kidney injury of septic mice. Transl Androl Urol. 2020;9(5):2192–2199. doi: 10.21037/tau-20-1173.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang R, Liu H, et al. Resveratrol treatment is associated with lipid regulation and inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) in rabbits fed a high-fat diet. Evid Based Complement Alternat Med. 2020;2020:9641582. doi: 10.1155/2020/9641582.
   PubMed Web of Science ®Google Scholar
• Jin W. Correlation analysis between the level of lipoprotein associated phospholipase A2 and the stage of nephropathy in patients with type 2 diabetes. China: Zhengzhou University of China. 2019.
   Google Scholar